Carfilzomib-based Chemotherapy for Multiple Myeloma

(CarMob Trial)

Overseen By Geneva Khan

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Hackensack Meridian Health

Disqualifiers: Heart disease, Uncontrolled hypertension, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 4 weeks

18 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine the optimal dose of Carfilzomib, a chemotherapy drug, for treating multiple myeloma, a type of blood cancer. It combines Carfilzomib with other drugs, such as Cyclophosphamide and Dexamethasone, to evaluate their combined effectiveness. Individuals with multiple myeloma who have previously received Carfilzomib may be suitable candidates for this trial, particularly if they have not fully responded to prior treatments. As a Phase 1 trial, the research focuses on understanding how the treatment functions in participants.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that carfilzomib, when used alone, is generally safe for patients with relapsed or refractory multiple myeloma, meaning most people tolerate it well. However, some side effects can occur. One study found that 20.22% of patients experienced heart-related issues, but more than half of these patients already had heart problems.

The FDA has approved carfilzomib for treating certain types of multiple myeloma, indicating that its safety has been reviewed and deemed acceptable for those conditions.

This study is in its early testing phase, focusing primarily on safety. It involves gradually increasing doses of carfilzomib combined with other drugs to help researchers determine the safest dose and monitor for any side effects. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Unlike the standard treatments for multiple myeloma, which often include drugs like bortezomib and lenalidomide, Carfilzomib in this trial acts as a proteasome inhibitor that specifically targets and disrupts protein breakdown in cancer cells. This method can potentially lead to more effective cancer cell elimination. Additionally, Carfilzomib is being tested at various dose levels to find the most effective and safest option, which could offer more personalized treatment strategies. Researchers are excited about Carfilzomib because it might provide a more potent and targeted approach, possibly leading to better outcomes for patients with multiple myeloma.

What evidence suggests that this trial's treatments could be effective for multiple myeloma?

Research has shown that Carfilzomib can help people with relapsed or hard-to-treat multiple myeloma live longer without disease progression. Studies have found that treatments based on Carfilzomib result in a median progression-free survival of about 6.3 months, meaning patients live for about 6.3 months during and after treatment without disease growth. In this trial, participants will receive Carfilzomib at various dose levels, including 56 mg/m², which studies have found provides a good balance of effectiveness and safety. Overall, Carfilzomib improves outcomes for patients with multiple myeloma, making it a promising treatment option. ^{6 7 8 9 10}

Are You a Good Fit for This Trial?

This trial is for adults over 18 with multiple myeloma who have had some treatment but not a complete response. They should expect to live more than 12 weeks, be in fairly good health with normal liver function and heart performance, and have an acceptable blood count. Women must test negative for pregnancy and agree to use contraception, as must men.

Inclusion Criteria

You need to have had a heart scan showing that your heart is pumping well within the last 6 months.

Participants must have detectable levels of specific proteins in their blood or urine that can be measured.

I have multiple myeloma with measurable indicators.

Exclusion Criteria

I have not had radiation therapy in the last 3 weeks.

I do not have any uncontrolled illnesses like high blood pressure, diabetes, infections, or liver disease.

I have undergone stem cell transplant or preparation for it.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive escalating doses of Carfilzomib in combination with Cyclophosphamide, Dexamethasone, and G-CSF for mobilization of peripheral blood stem cells

4 weeks

Weekly visits for dose administration

Stem Cell Collection

Peripheral blood stem cell collection begins after high dose G-CSF injections

1 week

Daily visits for stem cell collection

Autologous Stem Cell Transplant

Patients proceed to a melphalan-based autologous stem cell transplant

1 week

Follow-up

Participants are monitored for safety and effectiveness after the transplant

24 months

Monthly visits for disease parameter assessment

What Are the Treatments Tested in This Trial?

Interventions

• Carfilzomib

Trial Overview

The study tests different doses of Carfilzomib (20-70mg/m2) combined with Cyclophosphamide, Dexamethasone, and G-CSF in escalating groups using a '3+3 design' to find the best dose for stem cell transplant preparation in multiple myeloma patients.

How Is the Trial Designed?

Group I: Carfilzomib Mobilization - Dose Level 5 Experimental Treatment 4 Interventions

Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Group II: Carfilzomib Mobilization - Dose Level 4 Experimental Treatment 4 Interventions

Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Group III: Carfilzomib Mobilization - Dose Level 3 Experimental Treatment 4 Interventions

Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Group IV: Carfilzomib Mobilization - Dose Level 2 Experimental Treatment 4 Interventions

Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Group V: Carfilzomib Mobilization - Dose Level 1 Experimental Treatment 4 Interventions

Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Group VI: Carfilzomib Mobilization - Dose Level 0 Experimental Treatment 4 Interventions

Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF. For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing.

Carfilzomib is already approved in United States, European Union, Canada, Japan for the following indications:

Approved in United States as Kyprolis for:

• Multiple myeloma

Approved in European Union as Kyprolis for:

• Multiple myeloma

Approved in Canada as Kyprolis for:

• Multiple myeloma

Approved in Japan as Kyprolis for:

• Multiple myeloma

Who Is Running the Clinical Trial?

Hackensack Meridian Health

Lead Sponsor

Trials

141

Recruited

42,900+

Amgen

Industry Sponsor

Trials

1,508

Recruited

1,433,000+

Founded

1980

Headquarters

Thousand Oaks, USA

Known For

Human Therapeutics

Top Products

Enbrel, Prolia, Neulasta, Otezla

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London

Published Research Related to This Trial

Carfilzomib, a proteasome inhibitor approved for relapsing multiple myeloma, was associated with a case of fatal pulmonary toxicity in a 61-year-old male patient, highlighting a potential serious side effect of the drug.

The patient developed acute respiratory distress syndrome and diffuse alveolar hemorrhage shortly after starting carfilzomib, suggesting a direct link between the medication and the severe lung complications, which had not been previously reported.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™). Lataifeh, AR., Nusair, A.[2020]

In the ENDURANCE trial involving patients with newly diagnosed multiple myeloma, the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not improve progression-free survival compared to the standard treatment of bortezomib, lenalidomide, and dexamethasone (VRd).

These findings suggest that KRd may not be a more effective treatment option than the current standard of care for patients with NDMM.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carfilzomib Triplet Fails to Induce Superior PFS in Newly Diagnosed Multiple Myeloma. Skarzynski, J.[2021]

Carfilzomib shows significant efficacy in treating multiple myeloma, with a 28% complete response rate and a 93% overall response rate among 2,487 patients analyzed across 12 clinical trials.

While carfilzomib improves survival rates (93% progression-free survival at 1 year), it is associated with a higher incidence of cardiotoxicity compared to traditional treatments, although it does not significantly increase the risk of peripheral neuropathy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma：A Systematic Evaluation]. Luo, T., Xia, HL.[2020]

In a study of 138 Korean patients with relapsed/refractory multiple myeloma, carfilzomib combined with lenalidomide and dexamethasone (KRd) was associated with a higher risk of specific adverse events, including dyspnea, muscle spasms, and thrombocytopenia, particularly during the early treatment cycles.

Despite the increased risk of these side effects, most adverse events were of low severity (grade 1-2), suggesting that while carfilzomib has notable side effects, it can still be used effectively and safely in real-world treatment settings for RRMM.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records. Jang, HY., Lee, HK., Kim, CJ., et al.[2023]

Carfilzomib, when used in combination with lenalidomide and dexamethasone, significantly prolongs progression-free survival (PFS) by 8.7 months in patients with relapsed multiple myeloma, based on results from the phase III ASPIRE study involving a multinational patient population.

The combination therapy has a manageable safety profile, with low incidences of severe adverse events, suggesting it is a viable treatment option for patients who have received prior therapies, although overall survival data is still pending.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma. Hoy, SM.[2018]

Carfilzomib-containing combinations as frontline therapy for multiple myeloma showed a high overall response rate of 94% and a complete response rate of 21% across 13 trials involving 704 subjects.

The combination of carfilzomib with lenalidomide and dexamethasone (CFZ-LEN-DEX) resulted in a significantly higher complete response rate of 49% compared to other combinations, indicating it may be the most effective regimen for newly diagnosed patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials. Sheng, Z., Li, G., Li, B., et al.[2018]

Carfilzomib significantly improves progression-free survival, overall survival, and overall response rate in patients with relapsed/refractory multiple myeloma, based on evidence from 14 systematic reviews involving moderate quality data.

However, treatment with carfilzomib is associated with increased risks of cardiovascular events, nephrotoxicity, and serious infections, highlighting the need for careful monitoring and further research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews. Georgoulis, V., Haidich, AB., Bougioukas, KI., et al.[2022]

In patients with mild to moderate hepatic impairment, carfilzomib showed approximately 20-50% higher drug exposure compared to those with normal liver function, but this increase is not expected to be clinically significant due to the drug's pharmacokinetic variability.

The safety profile of carfilzomib in patients with advanced solid tumors was consistent with previous findings, although there was a noted increase in adverse events related to liver function abnormalities.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Brown, J., Plummer, R., Bauer, TM., et al.[2020]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9713064/

Carfilzomib usage patterns and outcomes in patients with ...

Median progression‐free survival for the overall cohort was 6.3 months with overall survival 19.7 months. This study provides a benchmark for carfilzomib‐based ...

2.

kyprolis.com

kyprolis.com/treatment-results

Efficacy | KYPROLIS® (carfilzomib)

KYPROLIS helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse and reach a complete response.

3.

nature.com

nature.com/articles/s41408-025-01256-2

Carfilzomib prescribing patterns and outcomes for relapsed ...

Our findings do not support improved outcomes with twice-weekly carfilzomib in RRMM. K56-1x may provide the best balance of efficacy, safety, and avoidance of ...

4.

kyprolis-hcp.com

kyprolis-hcp.com/combinations/kd-efficacy

Kd Efficacy | KYPROLIS® (carfilzomib)

Phase 3, randomized, open-label superiority study: (N=929) comparing Kd 56 mg/m 2 twice weekly to Vd in relapsed or refractory multiple myeloma patients.

5.

ashpublications.org

ashpublications.org/blood/article/144/Supplement%201/6992/526838/Real-World-Analysis-of-the-Efficacy-Prognosis-and

Real World Analysis of the Efficacy, Prognosis and Safety of ...

The median follow-up time was 9 (1-19) months, the estimated median PFS was 15 months, and the median OS was not reached. The cumulative PFS of ...

6.

kyprolis-hcp.com

kyprolis-hcp.com/dosing-and-administration/safety

Long-Term Safety | KYPROLIS® (carfilzomib)

Learn more about the long-term safety of KYPROLIS® for each combination for your patients with relapsed or refractory multiple myeloma (RRMM).

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC3815177/

Integrated safety profile of single-agent carfilzomib

These data demonstrate that single-agent carfilzomib has an acceptable safety profile in heavily pre-treated patients with relapsed/refractory multiple myeloma.

8.

msds.amgen.com

msds.amgen.com/kyprolis-safety-datasheet

Kyprolis® (carfilzomib)

Avoid inhalation, skin contact, eye contact, and accidental ingestions. Based on available data, the GHS classification criteria are not met. 2.1 - ...

9.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38769166/

Target trial emulation of carfilzomib safety among patients ...

This study aimed to evaluate carfilzomib's safety in Korea by comparing new users of KRd (carfilzomib, lenalidomide, and dexamethasone) to Rd (lenalidomide and ...

10.

ashpublications.org

ashpublications.org/blood/article/144/Supplement%201/7836/527298/Efficacy-and-Safety-of-Carfilzomib-Based-Regimens

Efficacy and Safety of Carfilzomib-Based Regimens in Multiple ...

Eighteen (20.22%) patients suffered cardiovascular events after carfilzomib treatment, but 10 of them already had cardiovascular abnormalities ...